- Home
- ERII vs JANX Comparison
ERII vs JANX Comparison
Compare ERII & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ERII | JANX |
|---|---|---|
| Founded | 1992 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 850.2M | 790.3M |
| IPO Year | 2008 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ERII | JANX |
|---|---|---|
| Price | $10.64 | $13.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | $16.50 | ★ $53.60 |
| AVG Volume (30 Days) | 600.4K | ★ 884.1K |
| Earning Date | 05-28-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.00 | N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $134,987,000.00 | $10,000,000.00 |
| Revenue This Year | $17.21 | N/A |
| Revenue Next Year | $21.97 | $209.90 |
| P/E Ratio | $25.52 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.59 | $12.12 |
| 52 Week High | $18.31 | $35.34 |
Technical Indicators
Market Signals| Indicator | ERII | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 24.85 | 50.79 |
| Support Level | N/A | $13.80 |
| Resistance Level | $14.74 | $15.49 |
| Average True Range (ATR) | 0.57 | 0.52 |
| MACD | -0.53 | 0.14 |
| Stochastic Oscillator | 15.50 | 59.16 |
Price Performance
Historical ComparisonAbout ERII Energy Recovery Inc.
Energy Recovery Inc is an engineering-driven technology company. It is engaged in engineering, designing, manufacturing and supplying solutions that make industrial processes more efficient and sustainable. The company operates in three segments, Water, Emerging Technologies and Corporate. It offers energy recovery devices (ERDs) and pumps as well as related products and services to the reverse osmosis desalination market. The company derives a majority of the revenue from the Water segment. Geographically, the company operates in the U.S. and other international countries.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.